Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mazindol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence
    NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence

    21 Oct 2024

    // ACCESSWIRE

    https://www.accesswire.com/933330/nls-pharmaceutics-secures-key-patent-in-japan-for-mazindol-er-in-the-treatment-of-heroin-dependence

    ACCESSWIRE
    21 Oct 2024
    Share Share
    NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model
    NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model

    28 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/867511/nls-pharmaceutics-reports-positive-results-from-study-ko-874-on-mazindols-neuroprotective-effects-in-narcoleptic-like-rat-model

    ACCESSWIRE
    28 May 2024
    Share Share
    NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER
    NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER

    03 Jul 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=765143&lang=en

    ACCESSWIRE
    03 Jul 2023
    Share Share
    NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450
    NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450

    14 Jun 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=761224&lang=en

    ACCESSWIRE
    14 Jun 2023
    Share Share
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)

    02 May 2023

    // BUSINESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=752432&lang=en

    BUSINESSWIRE
    02 May 2023
    Share Share
    NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER
    NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER

    27 Mar 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=745926&lang=en

    ACCESSWIRE
    27 Mar 2023
    Share Share